Fig. 6

(Abstract O8). a. Therapy of the clinically relevant spontaneous prostate tumor TRAMP/MICB model (Liu et al, 2013, JCI 123 (10) 4410 ) with CuraB10 (also called B10G5) or control IgG (placebo) at advanced stage via I.P. injection at the dose of 3.8 mg/KG body weight twice weekly for 8 weeks (b). Mice with CuraB-1o therapy all enjoyed longtime survived whereas mice in placebo group are succumbed to cancer (c). Prostate weight. Comparisons made between Placebo group and CuraB-10 group and between before and after treatment of CuraB-10. (d). Representative images of the prostate. Top showing large tumor burden. Bottom showing normal prostate size. (e). All mice in the control group developed metastasis whereas no metastasis was detected in animals received CuraB-10 therapy. In summary, the data demonstrate that CuraB-10 stand-alone therapy can effectively induce regression of primary tumors and eliminate metastasis